42 results on '"Lane, Roger M."'
Search Results
2. Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
3. Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
4. Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
5. Butyrylcholinesterase Kalow variant reduces age‐of‐onset of Alzheimer Disease in apolipoprotein ɛ4 carriers
6. Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
7. List of contributors
8. Antisense oligonucleotide drugs for neurological and neuromuscular disease
9. Translating Antisense Technology into a Treatment for Huntington’s Disease
10. Butyrylcholinesterase genotype and gender influence Alzheimer’s disease phenotype
11. Tau-targeting antisense oligonucleotide MAPTRxin mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
12. Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE ε4, and hyperhomocysteinemia in neurodegenerative dementias
13. A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder
14. Chirality and Drugs Used in Psychiatry: Nice to Know or Need to Know?
15. Rivastigmine versus placebo in hyperhomocysteinemic Parkinsonʼs disease dementia patients
16. Targeting Huntingtin Expression in Patients with Huntington’s Disease
17. Sertraline Treatment of Generalized Social Phobia: A 20-Week, Double-Blind, Placebo-Controlled Study
18. Author Correction: Tau-targeting antisense oligonucleotide MAPTRxin mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
19. [O2-17-02]: DISCOVERY AND EARLY CLINICAL DEVELOPMENT OF IONIS-MAPTRX , THE FIRST TAU-LOWERING ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH MILD AD
20. Understanding the Beneficial and Detrimental Effects of Donepezil and Rivastigmine to Improve their Therapeutic Value
21. Antidepressant drug development: Focus on triple monoamine reuptake inhibition
22. DISCOVERY AND EARLY CLINICAL DEVELOPMENT OF IONIS-MAPTRX, THE FIRST TAU-LOWERING ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH MILD AD
23. Restoration of positive mood states in major depression as a potential drug development target
24. Results of the first‐in‐human, randomized, double‐blind, placebo‐controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau mRNA in patients with...
25. Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype
26. Evaluation of Dementia Rating Scales in Parkinson’s Disease Dementia
27. Rivastigmine in Dementia Associated with Parkinson's Disease and Alzheimer's Disease: Similarities and Differences
28. Antidepressant drug development: Focus on triple monoamine reuptake inhibition.
29. Targeting acetylcholinesterase and butyrylcholinesterase in dementia
30. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
31. Double-Blind Placebo-Controlled Pilot Study of Sertraline in Military Veterans With Posttraumatic Stress Disorder
32. Forced titration as a confound in an SSRI comparator study of sertraline versus citalopram in the treatment of major depressive disorder
33. Prevention of Relapse in Generalized Social Phobia: Results of a 24-Week Study in Responders to 20 Weeks of Sertraline Treatment
34. Treatment of Dysthymia With Sertraline
35. Effects of SSRIs on Sexual Function
36. SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment
37. Evaluation of Dementia Rating Scales in Parkinson's Disease Dementia.
38. Conversion of dialdehydes into cyclic α-ketols by thiazolium salts: synthesis of cyclic 2-hydroxy-2-enones
39. Targeting acetylcholinesterase and butyrylcholinesterase in dementia
40. Targeting Huntingtin Expression in Patients with Huntington's Disease.
41. Translating Antisense Technology into a Treatment for Huntington's Disease.
42. Acetylcholinesterase and its inhibition in Alzheimer disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.